Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Core Innovation
The invention relates to non-peptidyl somatostatin receptor modulators, particularly compounds of Formula (I) and Formula (III), with an emphasis on modulation of somatostatin receptor subtype 2 (SSTR2). The compounds encompass broad substituent variations, including aminopiperidinyl-substituted pyridine and pyridazine compounds with benzodiazolyl, indolyl, and related heteroaryl variants. These compounds include specified pharmaceutically acceptable salts, solvates, diastereomeric mixtures, and individual enantiomers.
The disclosure describes pharmaceutical compositions comprising the compounds and at least one pharmaceutically acceptable excipient, alongside methods of treating diseases or conditions by modulating SSTR2 activity. The supplied patent content omits an explicitly described background problem or summary of the invention, while documented assay screening results report SSTR2 cAMP modulation, hSSTR2/hSSTR4 selectivity, and CYP2D6 and hERG inhibition for representative compounds across the series.
Claims Coverage
The claims define two inventive features across two independent claims covering a Formula (III) compound genus and a set of specifically named compounds.
Formula (III) compounds
Claim 1 covers a compound of Formula (III), or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomer thereof, defining alternatives for substituents and permitting specified substituents to form nitrogen-containing or other rings.
Specifically named compounds
Claim 17 covers a set of specifically named aminopiperidinyl-substituted pyridine compounds bearing aryl and benzodiazolyl, indolyl, imidazopyridine, or related heteroaryl groups, or pharmaceutically acceptable salts, solvates, diastereomeric mixtures, and individual enantiomers thereof.
The two independent claims encompass a structurally defined Formula (III) compound genus and specifically named compounds, while associated dependent claims further identify pharmaceutical compositions with pharmaceutically acceptable excipients and treatment methods modulating SSTR2 activity.
Stated Advantages
The specification identifies potential SSTR2 selectivity.
The specification identifies potential reduced CYP2D6 and/or hERG inhibition liability.
The specification identifies suitability for oral administration.
Documented Applications
Pharmaceutical compositions comprising a claimed compound or specified pharmaceutically acceptable form and at least one pharmaceutically acceptable excipient.
Treatment of a disease or condition in a mammal through modulation of SSTR2 activity, including acromegaly, neuroendocrine tumors, ophthalmic diseases or conditions, neuropathy, nephropathy, respiratory diseases or conditions, cancer, pain, neurodegenerative diseases or conditions, inflammatory diseases or conditions, and psychiatric diseases or conditions.
Interested in licensing this patent?